Education Featured Article
October 11, 2012
MEDL Mobile and Marlee Matlin Release Educational American Sign Language App
By Deepika Mala, TMCnet Contributor
Marlee Matlin, Academy Award-winning actress, has recently collaborated with MEDL Mobile, Inc. a pioneer in the creation, development, marketing and monetization of mobile apps to launch an educational American Sign Language app, called "Marlee Signs".
A user, with the help of "Marlee Signs" is able to learn the fundamentals of American Sign Language, from signed alphabet and basic vocabulary to common expressions in everyday life.
The app features high quality videos which show Marlee Matlin demonstrating the lessons. The “Spell” feature of the app allows users to get the spelling of any word in ASL by typing in a word and watching Marlee sign it back to them. Users are also allowed to watch any video in slow motion for greater detail and learn at their own pace by breaking down the lessons into individual videos.
"Working with Marlee Matlin has been a lot of fun! She was hysterical to work with on the set," said Dave Swartz, MEDL Co-founder and CCO, in a statement. "We believe that Marlee's breakthrough appeal will help introduce ASL to a broad new audience through the iPhone (News - Alert) and iPad."
"I wanted to create a simple, visual presentation of American Sign Language vocabulary that's the next best thing to taking a class," Marlee stated. "It's a great starting point for learning ASL the way it should - visually, in full motion, and not just static images on a page. It's not a substitute for taking a sign language class but I think it's the next best thing!"
In related TMC (News - Alert) news, MEDL Mobile, Inc. and famous hypnotist, Tyzen have released a family of mobile lessons designed to effectively deal with common problems such as losing weight, stress, quitting smoking and building confidence.
Edited by Brooke Neuman
LATEST EDUCATION NEWS
Kolltan Pharmaceuticals Announces Presentation of KTN3379 Interim Phase 1b Data at 2015 American Society of Clinical Oncology Annual Meeting
Acelarin® achieves very high disease control rates in patients with advanced gynaecological cancers in a Phase I/II setting
Ground-breaking Final Results of the First in Human Phase I/II Study with Acelarin in Advanced Solid Tumours
Studies Presented at 2015 ASCO Meeting Demonstrate Predictive Power of bioTheranostics' Breast Cancer Index? Molecular Test in Endocrine Therapy Decisions
Updated Positive Results from Two Trials of Cobimetinib in Combination with Vemurafenib for the Treatment of Patients with Advanced Melanoma Presented at 2015 ASCO Annual Meeting
Updated Data Showed Genentech's Investigational Combination of Cobimetinib and Zelboraf (Vemurafenib) Helps People With Advanced Melanoma Live for a Year Without Their Disease Worsening
Genentech's Gazyva® Extended the Time People With Refractory Indolent Non-Hodgkin's Lymphoma Lived Without Their Disease Worsening